Opinion|Videos|May 3, 2024
Overcoming Limitations and Barriers Associated with Treating Pulmonary Arterial Hypertension
Author(s)Ioana Preston, MD
An expert on pulmonary arterial hypertension discusses the limitations of current therapies and the barriers to early diagnosis.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What are the limitations of current pulmonary arterial hypertension (PAH) therapies that primarily focus on symptom management, and how do they impact patient outcomes?
- How does the high disease burden associated with PAH affect patients' quality of life and functional status?
- What are the barriers to early diagnosis and initiation of treatment for PAH, and how do they contribute to poor outcomes?
Advertisement
Related to this article
ASPEN links green sputum to neutrophils and exacerbations; brensocatib (DPP1) lowers purulence, while meta-analysis supports fewer flare-ups in bronchiectasis.
Narcolepsy and idiopathic hypersomnia can go undiagnosed for years, and Epworth and RU-SATED screening help clinicians spot true sleepiness sooner.
At CHEST 2026, 3 speakers explained why respiratory medications stay expensive, assessed what recent federal, state, and industry fixes have achieved, and urged clinicians to use their voices on behalf of patients.
Experts at CHEST 2026 urge pulmonologists to keep lung cancer in mind for younger patients who never smoked, to order screening and biomarker testing themselves, and to advocate for patients' access to care.
FDA granted accelerated approval to dostarlimab-gxly for dMMR or MSI-H locally advanced rectal cancer based on interim phase 2 AZUR-1 results.
Phentolamine 0.75% (Ryzumvi) won FDA approval for presbyopia based on the phase 3 VEGA-2 and VEGA-3 trials.
Nearly 3 in 4 bariatric surgery candidates had clinical obesity, a phenotype that BMI alone did not distinguish from preclinical obesity.
Satralizumab, a first-in-class IL-6 receptor inhibitor, was approved for adults with thyroid eye disease based on the phase 3 SatraGO program.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Ryzumvi for Presbyopia, Expanding its Label
2
How Flatiron Health’s Network Chief Is Building the Future For (and With) Community Oncology Practices
3
Patents, Rebates, and a Policy Patchwork Keep Inhalers Costly, Panelists Say
4
FDA Grants Accelerated Approval to Dostarlimab for dMMR Rectal Cancer
5